Moleculin Biotech wins Mexican patent for lung-targeted liposomal Annamycin through 2040

Bitget2026/09/23 12:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moleculin Biotech won a Mexican patent covering its lung-targeted liposomal formulation of Annamycin.
The protection runs through Nov. 23, 2040, extending exclusivity for the technology in Mexico.
Annamycin is being evaluated in the pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230825PRIMZONEFULLFEED9832071) on September 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moleculin Biotech wins Mexican patent for lung-targeted liposomal Annamycin through 2040

You may also like

Crypto prices